CA3026323A1 - Formulation pharmaceutique de cineol et d'amoxicilline - Google Patents

Formulation pharmaceutique de cineol et d'amoxicilline Download PDF

Info

Publication number
CA3026323A1
CA3026323A1 CA3026323A CA3026323A CA3026323A1 CA 3026323 A1 CA3026323 A1 CA 3026323A1 CA 3026323 A CA3026323 A CA 3026323A CA 3026323 A CA3026323 A CA 3026323A CA 3026323 A1 CA3026323 A1 CA 3026323A1
Authority
CA
Canada
Prior art keywords
amoxicillin
cineol
formulation
powder
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3026323A
Other languages
English (en)
French (fr)
Inventor
Adnane Remmal
Ahmed Amine AKHMOUCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Scientific Developments
Original Assignee
Advanced Scientific Developments
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR1655017A external-priority patent/FR3052066B1/fr
Priority claimed from MA39084A external-priority patent/MA39084A1/fr
Priority claimed from MA39085A external-priority patent/MA39085B1/fr
Priority claimed from FR1655018A external-priority patent/FR3052065B1/fr
Application filed by Advanced Scientific Developments filed Critical Advanced Scientific Developments
Publication of CA3026323A1 publication Critical patent/CA3026323A1/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3026323A 2016-06-02 2017-06-02 Formulation pharmaceutique de cineol et d'amoxicilline Pending CA3026323A1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
MA39085 2016-06-02
FR1655017A FR3052066B1 (fr) 2016-06-02 2016-06-02 Formulation pharmaceutique de cineol et d'amoxicilline
FR1655018 2016-06-02
MA39084A MA39084A1 (fr) 2016-06-02 2016-06-02 Formulation pharmaceutique de cineol et d'amoxicilline
FR1655017 2016-06-02
MA39085A MA39085B1 (fr) 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne
FR1655018A FR3052065B1 (fr) 2016-06-02 2016-06-02 Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne
MA39084 2016-06-02
PCT/MA2017/000014 WO2017209588A2 (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cinéol et d'amoxicilline

Publications (1)

Publication Number Publication Date
CA3026323A1 true CA3026323A1 (fr) 2017-12-07

Family

ID=59399462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026323A Pending CA3026323A1 (fr) 2016-06-02 2017-06-02 Formulation pharmaceutique de cineol et d'amoxicilline

Country Status (8)

Country Link
US (2) US11872216B2 (enExample)
EP (1) EP3463479A2 (enExample)
JP (1) JP7033586B2 (enExample)
CN (1) CN109562182A (enExample)
CA (1) CA3026323A1 (enExample)
MA (1) MA44286A (enExample)
SA (1) SA518400554B1 (enExample)
WO (1) WO2017209588A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017209588A2 (fr) * 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline
WO2021110915A1 (fr) 2019-12-04 2021-06-10 Pranarôm International S.A. Procede de transformation d'une huile essentielle
DE202021106639U1 (de) 2021-10-08 2023-01-10 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft mit beschränkter Haftung Neue Therapiekonzepte für die Behandlung von Otitis
CN118267361B (zh) * 2024-05-31 2024-08-23 潍坊格润药业有限公司 一种兽用复方阿莫西林可溶性粉

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102309473A (zh) * 2003-07-17 2012-01-11 纽约市哥伦比亚大学托管会 含有季铵化合物及精油和/或精油成分的协同组合的抗微生物组合物
WO2006120495A1 (fr) 2005-05-13 2006-11-16 Advanced Scientific Developements Composition pharmaceutique comprenant un antiviral, an antitumoral ou un antiparasitaire, et un actif choisi parmi le carveol, le thymol, l’eugenol, le borneol et le carvacrol
WO2006120494A1 (fr) 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un antibacterien et une substance active choisie parmi le carveol, le thymol, l’eugenol, le borneol et les carvacrol
WO2006120496A1 (fr) 2005-05-13 2006-11-16 Advanced Scientific Developements Combinaison pharmaceutique comprenant un agent antifongique et un actif choisi parmi le carveol, l’ eugenol, le thymol, le borneol, et le carvacrol
US20080139526A1 (en) * 2006-12-06 2008-06-12 Donald Treacy Modified release dosage forms of amoxicillin
DE102006007830A1 (de) * 2006-02-17 2007-08-30 Grünenthal GmbH Lagerstabile orale Darreichungsform von Amoxicillin und Clavulansäure
AU2009235426A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
FR2937549B1 (fr) 2008-10-29 2011-04-01 Centre Nat Rech Scient Nanoparticules de derives beta-lactamine
CN103391774B (zh) * 2010-12-09 2016-09-28 Septeos公司 包含反式-肉桂醛的药物组合物及其在治疗感染中的用途
EP2678004A1 (en) 2011-02-25 2014-01-01 Eydo Pharma Nanocapsulation of essential oils for preventing or curing infectious diseases alone or with an antibiotic
NZ707855A (en) 2012-11-06 2018-11-30 Rochal Ind Llc Delivery of biologically-active agents using volatile, hydrophobic solvents
MA35295B1 (fr) 2012-12-31 2014-08-01 Advanced Scient Developments Complexe moleculaire detoxifiant et antimicrobien
FR3025719A1 (fr) * 2014-09-15 2016-03-18 Septeos Antimicrobiens potentialises
WO2017209588A2 (fr) * 2016-06-02 2017-12-07 Advanced Scientific Developements Formulation pharmaceutique de cinéol et d'amoxicilline

Also Published As

Publication number Publication date
WO2017209588A2 (fr) 2017-12-07
JP7033586B2 (ja) 2022-03-10
JP2019521178A (ja) 2019-07-25
WO2017209588A3 (fr) 2018-03-15
SA518400554B1 (ar) 2024-07-29
MA44286A (fr) 2019-01-09
US11872216B2 (en) 2024-01-16
US20190255024A1 (en) 2019-08-22
BR112018074913A2 (pt) 2019-03-12
EP3463479A2 (fr) 2019-04-10
US20240148702A1 (en) 2024-05-09
CN109562182A (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
US20240148702A1 (en) Pharmaceutical formulation comprising cineole and amoxicillin
EP2437737B1 (fr) Composition comprenant au moins du trans-cinnamaldehyde et son utilisation dans le traitement des infections bacteriennes plus particulierement dans le traitement des maladies nosocomiales
CA2606875C (fr) Combinaison pharmaceutique comprenant un antibiotique et une substance active choisie parmi le carveol, le thymol, le carvacrol, l'alpha-ionone et beta-ionone
US20210161862A1 (en) Use of statins for periodontal disease and bone regeneration
EP3429611B1 (fr) Polycomplexes de composes poly-lysine pour la prevention et/ou la lutte contre la sclerose laterale amyotrophique
EP3193936B1 (fr) Antimicrobiens potentialises
FR3052066B1 (fr) Formulation pharmaceutique de cineol et d'amoxicilline
ES2316957T3 (es) Composicion medicinal para tratar la infeccion con staphylococcus aureus resistente a farmacos.
Sekar et al. Characterization and Formulation of Miswak Film for the Treatment of Chronic Periodontitis: An: In Vitro: Study
FR3052065B1 (fr) Combinaison de cineol et d'amoxicilline pour une utilisation dans le traitement d'une infection bacterienne
EP0310476A1 (fr) Composition inhibitrice ou destructrice d'au moins un être vivant unicellulaire renfermant du fluor F- et du lithium Li+
FR3021218A1 (fr) Utilisation du cinnamaldehyde en association avec de l'eugenol et/ou du carvacrol pour lutter contre la resistance aux antibiotiques
EA047849B1 (ru) Фармацевтическая композиция, содержащая комплексы амоксициллина, и ее применение
EA041153B1 (ru) Фармацевтический препарат, включающий цинеол и амоксициллин
FR2833173A1 (fr) Preparation antipyretique renfermant du xylitol
BR112018074913B1 (pt) Formulação farmacêutica de cineol e amoxicilina
BE505709A (enExample)
FR3149501A1 (fr) Composition a base d’huile essentielle de c. cassia et utilisations de celle-ci
CA3079023A1 (fr) Utilisation de la cloxacilline pour inhiber/empecher la formation de biofilm
WO1996020714A1 (fr) Composition antifongique contenant du crotamiton et de d'aldehyde salicylique
FR2988562A1 (fr) Activite antibacterienne de ludwigia peploides
FR2882255A1 (fr) Spheroides prepares a partir d'un principe actif isole d'origine vegetale et d'une solution d'origine vegetale contenant le principe actif ou un precurseur de celui-ci

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525

EEER Examination request

Effective date: 20220525